Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Bull: Successful launch and rapid adoption of new therapies reignite mid-single-digit top-line growth, driving operating leverage and margin expansion.
Pipeline Stagnation: Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Medtronic is a dominant, entrenched player in the global medical devices industry. While near-term growth is sluggish and quarterly earnings are compressed, its immense scale, high switching costs for healthcare providers, and reliable free cash flow easily support a high dividend payout, fitting the classic mature dividend archetype.
Immense scale in the global medical devices industry.
High switching costs for healthcare providers.
Adoption of next-generation therapies in Diabetes and Cardiovascular drives operating leverage and multiple expansion.
Buy. Medtronic's deeply entrenched portfolio and cash generation capabilities are severely undervalued by a market fixated on near-term trailing stagnation.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
A prolonged period of sluggish top-line growth combined with intense pricing pressure and hospital capital constraints severely compresses operating margins below the 19.5% baseline, threatening Medtronic's reliable free cash flow and forcing a cut to its high dividend payout.
Immense scale in the global medical devices industry.
High switching costs for healthcare providers.
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $6.3B after capex $1.8B, with terminal value at 68.7% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest toward 14x.
High dividend payout limits aggressive M&A, forcing reliance on internal R&D and pipeline execution.
Adoption of next-generation therapies in Diabetes and Cardiovascular drives operating leverage and multiple expansion.
Healthcare system capital spending constraints and deferred procedures delay volume recovery.
High dividend payout limits aggressive M&A, forcing reliance on internal R&D and pipeline execution.
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
The 1.73% implied growth hurdle from the Reverse DCF confirms extreme market pessimism. Our multi-model synthesis relies heavily on structural cash generation to bypass near-term trailing noise.
Buy. The current share price fails to credit the immense durability of Medtronic's free cash flow engine, providing a large margin of safety against sluggish top-line growth.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Intense competition and pricing pressure erode gross margins, threatening the dividend growth trajectory and resulting in severe multiple compression.
Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Macroeconomic pressures force severe hospital capital constraints and widespread deferral of elective procedures, crushing revenue growth to negative territory.
Pricing pressure and margin erosion reduce free cash flow such that the 79% dividend payout becomes unsustainable, triggering massive multiple compression.
The five developments that would weaken our investment case.
Anemic top-line expansion indicates deepening hospital procurement freezes and market share erosion across core medical device categories. Sluggish volume expansion prevents positive operating leverage, impairing cash flow generation necessary to support ongoing product development and defensive dividend coverage.
Current:3.6% for the period ended 2025-04-30
Alert ifRevenue growth falls below 1.5% over a fiscal year
Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Current:6.6% as of 2026-05-12
Alert ifROIC declines below 5.0% over a twelve-month period
Persistent margin degradation reflects an inability to offset customer pricing pressure and medical inflation through cost containment. Compressing operating margins directly reduces free cash flow generation, eliminating bottom-line operating leverage and endangering the company's valuation multiple relative to peers.
Current:19.5% for the period ended 2025-04-30
Alert ifOperating margin falls below 19.5% over two consecutive fiscal quarters
Escalating cash commitment to shareholder payouts leaves little cushion against revenue volatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
Current:79% as of 2026-05-12
Alert ifDividend payout ratio exceeds 90% of free cash flow over an annual period
Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
Current:Active pipeline development programs as of 2026-05-12
Alert if1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Discount the explicit dividend path and its Gordon-growth terminal value at cost of equity.
Solve for the growth rate that makes the model value equal the report-date share price.
Successful launch and rapid adoption of new therapies reignite mid-single-digit top-line growth, driving operating leverage and margin expansion.
Medtronic maintains stable free cash flow and dividend payouts despite sluggish near-term execution, supported by entrenched market share.
If revenue growth misses the 1.5% hurdle, shares likely de-rate further; if Cardiovascular and Diabetes post mid-single-digit growth, expect modest multiple expansion toward 14x.
Warning level: Revenue growth falls below 1.5% over a fiscal year. Anemic top-line expansion indicates deepening hospital procurement freezes and market share erosion across core medical device categories. Sluggish volume expansion prevents positive operating leverage, impairing cash flow generation necessary to support ongoing product development and defensive dividend coverage.
Warning level: ROIC declines below 5.0% over a twelve-month period. Sub-par capital efficiency indicates that elevated capital outlays are failing to produce accretive operating profits. Generating returns below the corporate hurdle rate erodes economic value and restricts capital redeployment toward high-growth medtech innovations, weakening long-term competitive differentiation.
Warning level: Operating margin falls below 19.5% over two consecutive fiscal quarters. Persistent margin degradation reflects an inability to offset customer pricing pressure and medical inflation through cost containment. Compressing operating margins directly reduces free cash flow generation, eliminating bottom-line operating leverage and endangering the company's valuation multiple relative to peers.
Warning level: Dividend payout ratio exceeds 90% of free cash flow over an annual period. Escalating cash commitment to shareholder payouts leaves little cushion against revenue volatility or unexpected clinical liabilities. Exceeding sustainable cash boundaries forces either an outright dividend reduction or debt-funded shareholder returns, destroying the core defensive income thesis and triggering severe multiple compression.
Warning level: 1 or more formal FDA rejections or Phase 3 clinical trial terminations in Cardiovascular or Diabetes pipelines within a 12-month period. Major regulatory or clinical setbacks freeze critical product launch cycles in high-margin growth categories. Failing to refresh innovative offerings allows agile competitors to permanently capture market share, undermining premium pricing power and eliminating key anticipated drivers of mid-single-digit top-line acceleration.
| $31.23B |
| $32.36B |
| $33.54B |
| +1.9% |
| Gross profit | $21.54B | $20.51B | $21.15B | $21.91B | +0.6% |
| Operating income | $6.07B | $6.00B | $5.56B | $6.36B | +1.6% |
| Net income | $5.04B | $3.76B | $3.68B | $4.66B | -2.6% |
| EPS (diluted) | $3.73 | $2.82 | $2.76 | $3.61 | -1.1% |
| EBITDA | $8.78B | $8.70B | $8.20B | $9.22B | +1.6% |
| R&D | $2.75B | $2.70B | $2.74B | $2.73B | -0.2% |
| SG&A | $10.29B | $10.42B | $10.74B | $10.85B | +1.8% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Revenue | 33,537,000,000 |
|---|---|
| Cost of revenue | 11,632,000,000 |
| Gross profit | 21,905,000,000 |
| Operating expenses | 15,365,000,000 |
| Operating income | 6,540,000,000 |
| Non-operating items and tax | -1,878,000,000 |
| Net income | 4,662,000,000 |
| Total assets | 91,680,000,000 |
|---|---|
| Cash | 2,218,000,000 |
| Current assets | 23,814,000,000 |
| Total liabilities | 43,424,000,000 |
| Current liabilities | 12,879,000,000 |
| Shareholders’ equity | 48,024,000,000 |
Point-in-time financial data used in the 2026-05-12 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-04-30 | 31.7B | 8.8B | 5B | 7.3B | 6B | 1.4B | 2.7B | 359M | 2.5B | 3.4B | -1M | — | — | — | — | 3.7B | 24.1B | 18.6% | — | 5.9% | — |
| 2023-04-30 | 31.2B | 8.7B | 3.8B | 6B | 4.6B | 1.5B | 2.7B | 355M | 645M | 3.6B | -598M | — | — | — | — | 1.5B | 24.4B | 18.7% | — | 6.2% | — |
| 2024-04-30 | 32.4B | 8.2B | 3.7B | 6.8B | 5.2B | 1.6B | 2.6B | 393M | 2.1B | 3.7B | 1.1B | — | — | — | — | 1.3B | 25B | 17.1% | — | 7.3% | — |
| 2025-04-30 | 33.5B | 9.2B | 4.7B | 7B | 5.2B | 1.9B | 2.9B | 429M | 3.2B | 3.6B | 2.1B | — | — | — | — | 2.2B | 28.5B | 19.5% | — | — | — |
MDT trades at 12.7x forward earnings against a peer median of 14.4x; EV/EBITDA of 12.2x against a peer median of 16.2x; 6 peers.
| Stryker Corporation |
| 17.6x |
| 4.5x |
| 17.3x |
| 15.2% |
| 17.8% |
| BSX | Boston Scientific Corporation | 14.4x | 3.9x | 16.2x | 14.7% | 20.6% |
| EW | Edwards Lifesciences Corporation | 22.9x | 7.0x | 22.6x | 10.5% | 31.2% |
| GEHC | GE HealthCare Technologies Inc. | 11.5x | 1.3x | 10.4x | 19.5% | 11.1% |
